S&P raises rating on Las Vegas Sands (LVS) from B to BB-; outlook Stable
- Alexion Pharma (ALXN) to Acquire Synageva BioPharma (GEVA) for $230/Share
- April ADP Employment Change 169K vs 200K Expected
- Pre-Open Stock Movers 05/06: (GEVA) (BRDR) (FATE) (MGI) Higher; (WLT) (ZU) (NDLS) Lower (more...)
- Herbalife (HLF) Tops Q1 EPS by 28c; Boosts FY15 EPS Outlook
- Twitter (TWTR) CFO Buys ~7K Shares
S&P raises rating on Las Vegas Sands (NYSE: LVS) from B to BB-; outlook Stable
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macau Casino Revenue Stabilizes in April But Any Rally Could be 'Short Lived', Says Analyst (LVS) (MGM) (MPEL) (WYNN)
- FBR Capital Downgrades Nationstar Mortgage (NSM) to Underperform
- TrovaGene (TROV) Price Target to $9 at Piper Jaffray Post Q1
Create E-mail Alert Related CategoriesCredit Ratings
Related EntitiesStandard & Poor's
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!